# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Yul Brynner (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML020-SYN-TD
- Date: 1983-09-01
- Fictional facility: St. Posthumous Health Center
- Fictional author: Simon Achterberg, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- His voice has become weak and breathy, and he cannot sing or project on stage **S**
- He wants to get back to performing and to keep working for as long as he can **S**
- He wants people to know what smoking did to him **S**

## Your goals

- Tissue diagnosis, full staging, PD-L1, and comprehensive biomarker results before any systemic therapy, within three weeks of presentation. Target: 1983-09-22. Recorded outcome: Diagnosis and stage by two weeks; PD-L1 at two weeks and tissue sequencing at three weeks; pembrolizumab started the day the sequencing was reviewed. **S**
- First palliative care visit within eight weeks of diagnosis. Target: 1983-10-13. Recorded outcome: Seen by the palliative care team two weeks after diagnosis. **S**
- A voice strong enough for rehearsal by the second cycle. Target: 1983-10-13. Recorded outcome: Louder, less breathy voice one week after injection medialization; light rehearsal resumed with voice therapy. **S**
- No grade 2 or higher immune-related adverse event missed: laboratory panel before each infusion and symptom review at each visit. Target: 1983-10-13. Recorded outcome: Panels normal before cycles 1 and 2; no symptoms of colitis, pneumonitis, hepatitis, or endocrine dysfunction. **S**
- Zoledronic acid started only after a dental examination and normal calcium and kidney function. Target: 1983-10-13. Recorded outcome: Dental examination three weeks earlier; calcium 9.4 and eGFR 92; first dose with cycle 2. **S**

## What we agreed to do

- Thoracic oncology consultation for the tissue diagnosis, stage, biomarker plan, first-line therapy, the place of radiation and a bone-modifying agent, and monitoring. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026) **S**
- Staging and tissue diagnosis: FDG PET-CT, brain MRI with contrast, and endobronchial ultrasound-guided needle aspiration of the highest-stage node, with enough tissue for PD-L1 and comprehensive next-generation sequencing, and plasma cell-free DNA testing in parallel. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026) **S**
- First-line systemic therapy chosen by biomarkers once sequencing excludes an actionable alteration: pembrolizumab 200 mg every 3 weeks for PD-L1 50 percent or more, with response CT every 6 to 12 weeks; switch to 400 mg every 6 weeks to fit the tour once stable. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026) **S**
- Immune-related adverse event monitoring: TSH and free T4, liver tests, creatinine, glucose, and blood count before each infusion; morning cortisol at baseline and for symptoms; written list of warning symptoms (diarrhea, cough or breathlessness, rash, yellowing, severe fatigue or headache) with a 24-hour oncology telephone line. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021) **S**
- Early integrated palliative care alongside cancer treatment, starting within eight weeks of diagnosis, with symptom (ESAS) and distress screening at each visit and advance care planning. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017); NCCN Clinical Practice Guidelines in Oncology: Distress Management (2026) **S**
- If bone metastases are confirmed: zoledronic acid 4 mg every 12 weeks after a dental examination, with calcium and vitamin D and calcium and creatinine checks before each dose; palliative radiation only if a lesion becomes painful or threatens fracture. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026) **S**
- Voice and work: injection medialization of the left vocal fold, voice therapy with a speech-language pathologist, infusions scheduled on his day off, and a graded return to rehearsal and performance as he chooses. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026) **S**
- Tobacco: confirm abstinence at each visit; no cessation treatment needed; record the smoking history for his care team. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026) **S**

## Follow-up

- 1983-09-01: New patient visit for six weeks of hoarseness, with a left upper lobe mass on same-day CT **S**
- 1983-09-15: Diagnosis and staging review with thoracic oncology consultation **S**
- 1983-09-22: Biomarker results and start of first-line pembrolizumab **S**
- 1983-10-13: Cycle 2 review: immune-related adverse event monitoring, symptoms, and return to work **S**
- 1983-10-27: Periodic adult preventive visit **S**

This teaching document does not replace care from a qualified clinician.
